nodes	percent_of_prediction	percent_of_DWPC	metapath
Tacrolimus—ORM1—Vismodegib—skin cancer	0.159	0.245	CbGbCtD
Tacrolimus—ORM1—Vemurafenib—skin cancer	0.126	0.194	CbGbCtD
Tacrolimus—ALB—Vismodegib—skin cancer	0.0669	0.103	CbGbCtD
Tacrolimus—ALB—Vemurafenib—skin cancer	0.0529	0.0816	CbGbCtD
Tacrolimus—ABCB1—Vismodegib—skin cancer	0.035	0.054	CbGbCtD
Tacrolimus—CYP3A4—Temozolomide—skin cancer	0.0302	0.0467	CbGbCtD
Tacrolimus—CYP3A4—Imiquimod—skin cancer	0.0302	0.0467	CbGbCtD
Tacrolimus—ALB—Fluorouracil—skin cancer	0.0238	0.0367	CbGbCtD
Tacrolimus—CYP3A4—Vismodegib—skin cancer	0.021	0.0323	CbGbCtD
Tacrolimus—CYP3A7—Docetaxel—skin cancer	0.0194	0.03	CbGbCtD
Tacrolimus—CYP3A7-CYP3A51P—Docetaxel—skin cancer	0.0194	0.03	CbGbCtD
Tacrolimus—ABCB1—Dactinomycin—skin cancer	0.0184	0.0284	CbGbCtD
Tacrolimus—CYP3A4—Vemurafenib—skin cancer	0.0166	0.0256	CbGbCtD
Tacrolimus—CYP3A5—Docetaxel—skin cancer	0.0146	0.0225	CbGbCtD
Tacrolimus—ABCB1—Docetaxel—skin cancer	0.00949	0.0146	CbGbCtD
Tacrolimus—MTOR—leg—skin cancer	0.00646	0.083	CbGeAlD
Tacrolimus—MTOR—forelimb—skin cancer	0.00641	0.0824	CbGeAlD
Tacrolimus—MTOR—hindlimb—skin cancer	0.00577	0.0741	CbGeAlD
Tacrolimus—CYP3A4—Docetaxel—skin cancer	0.00569	0.00877	CbGbCtD
Tacrolimus—MTOR—appendage—skin cancer	0.00495	0.0636	CbGeAlD
Tacrolimus—ABCA5—nipple—skin cancer	0.00399	0.0513	CbGeAlD
Tacrolimus—PPP3CA—hair follicle—skin cancer	0.00398	0.0511	CbGeAlD
Tacrolimus—MTOR—blood vessel—skin cancer	0.00275	0.0354	CbGeAlD
Tacrolimus—PPP3CA—nipple—skin cancer	0.0027	0.0346	CbGeAlD
Tacrolimus—ABCA5—mammalian vulva—skin cancer	0.00233	0.03	CbGeAlD
Tacrolimus—ABCA5—female reproductive system—skin cancer	0.002	0.0256	CbGeAlD
Tacrolimus—MTOR—neck—skin cancer	0.00197	0.0253	CbGeAlD
Tacrolimus—PPP3CA—connective tissue—skin cancer	0.00191	0.0246	CbGeAlD
Tacrolimus—FKBP1A—nipple—skin cancer	0.00179	0.023	CbGeAlD
Tacrolimus—FKBP1A—neck—skin cancer	0.00177	0.0228	CbGeAlD
Tacrolimus—ABCA5—head—skin cancer	0.00167	0.0214	CbGeAlD
Tacrolimus—PPP3CA—mammalian vulva—skin cancer	0.00157	0.0202	CbGeAlD
Tacrolimus—MTOR—connective tissue—skin cancer	0.00141	0.0181	CbGeAlD
Tacrolimus—PPP3CA—lymphoid tissue—skin cancer	0.0014	0.018	CbGeAlD
Tacrolimus—PPP3CA—female reproductive system—skin cancer	0.00135	0.0173	CbGeAlD
Tacrolimus—MTOR—epithelium—skin cancer	0.00134	0.0172	CbGeAlD
Tacrolimus—MTOR—skin of body—skin cancer	0.00127	0.0164	CbGeAlD
Tacrolimus—FKBP1A—connective tissue—skin cancer	0.00127	0.0163	CbGeAlD
Tacrolimus—FKBP1A—epithelium—skin cancer	0.00121	0.0155	CbGeAlD
Tacrolimus—ABCA5—lymph node—skin cancer	0.00117	0.015	CbGeAlD
Tacrolimus—MTOR—mammalian vulva—skin cancer	0.00116	0.0149	CbGeAlD
Tacrolimus—FKBP1A—skin of body—skin cancer	0.00115	0.0147	CbGeAlD
Tacrolimus—PPP3CA—head—skin cancer	0.00113	0.0145	CbGeAlD
Tacrolimus—FKBP1A—mammalian vulva—skin cancer	0.00105	0.0134	CbGeAlD
Tacrolimus—MTOR—lymphoid tissue—skin cancer	0.00103	0.0133	CbGeAlD
Tacrolimus—MTOR—female reproductive system—skin cancer	0.000996	0.0128	CbGeAlD
Tacrolimus—FKBP1A—lymphoid tissue—skin cancer	0.000929	0.0119	CbGeAlD
Tacrolimus—FKBP1A—female reproductive system—skin cancer	0.000896	0.0115	CbGeAlD
Tacrolimus—MTOR—head—skin cancer	0.000832	0.0107	CbGeAlD
Tacrolimus—PPP3CA—lymph node—skin cancer	0.000789	0.0101	CbGeAlD
Tacrolimus—FKBP1A—head—skin cancer	0.000748	0.00962	CbGeAlD
Tacrolimus—ORM1—female reproductive system—skin cancer	0.000701	0.00901	CbGeAlD
Tacrolimus—MTOR—lymph node—skin cancer	0.000583	0.00749	CbGeAlD
Tacrolimus—ABCB1—blood vessel—skin cancer	0.000573	0.00736	CbGeAlD
Tacrolimus—FKBP1A—lymph node—skin cancer	0.000524	0.00673	CbGeAlD
Tacrolimus—ORM1—lymph node—skin cancer	0.00041	0.00527	CbGeAlD
Tacrolimus—ALB—lymph node—skin cancer	0.00036	0.00462	CbGeAlD
Tacrolimus—CYP3A4—female reproductive system—skin cancer	0.000293	0.00376	CbGeAlD
Tacrolimus—ABCB1—epithelium—skin cancer	0.000279	0.00358	CbGeAlD
Tacrolimus—ABCB1—mammalian vulva—skin cancer	0.000242	0.00311	CbGeAlD
Tacrolimus—ABCB1—lymphoid tissue—skin cancer	0.000215	0.00276	CbGeAlD
Tacrolimus—ABCB1—female reproductive system—skin cancer	0.000207	0.00266	CbGeAlD
Tacrolimus—ABCB1—head—skin cancer	0.000173	0.00222	CbGeAlD
Tacrolimus—Erythema—Temozolomide—skin cancer	0.000122	0.000507	CcSEcCtD
Tacrolimus—Breast disorder—Docetaxel—skin cancer	0.000122	0.000505	CcSEcCtD
Tacrolimus—Discomfort—Bleomycin—skin cancer	0.000122	0.000505	CcSEcCtD
Tacrolimus—Malaise—Dactinomycin—skin cancer	0.000122	0.000505	CcSEcCtD
Tacrolimus—Cramp muscle—Docetaxel—skin cancer	0.000122	0.000504	CcSEcCtD
Tacrolimus—Toxic epidermal necrolysis—Docetaxel—skin cancer	0.000122	0.000504	CcSEcCtD
Tacrolimus—ABCB1—lymph node—skin cancer	0.000121	0.00156	CbGeAlD
Tacrolimus—Leukopenia—Dactinomycin—skin cancer	0.000121	0.000501	CcSEcCtD
Tacrolimus—Dysgeusia—Temozolomide—skin cancer	0.00012	0.000496	CcSEcCtD
Tacrolimus—Asthenia—Imiquimod—skin cancer	0.00012	0.000495	CcSEcCtD
Tacrolimus—Confusional state—Bleomycin—skin cancer	0.000119	0.000494	CcSEcCtD
Tacrolimus—Anaphylactic shock—Bleomycin—skin cancer	0.000118	0.00049	CcSEcCtD
Tacrolimus—Oedema—Bleomycin—skin cancer	0.000118	0.00049	CcSEcCtD
Tacrolimus—Back pain—Temozolomide—skin cancer	0.000118	0.00049	CcSEcCtD
Tacrolimus—Pruritus—Imiquimod—skin cancer	0.000118	0.000488	CcSEcCtD
Tacrolimus—Infection—Bleomycin—skin cancer	0.000118	0.000487	CcSEcCtD
Tacrolimus—Dysphagia—Docetaxel—skin cancer	0.000117	0.000483	CcSEcCtD
Tacrolimus—Nausea—Vemurafenib—skin cancer	0.000116	0.00048	CcSEcCtD
Tacrolimus—Thrombocytopenia—Bleomycin—skin cancer	0.000116	0.00048	CcSEcCtD
Tacrolimus—Arrhythmia—Fluorouracil—skin cancer	0.000116	0.000479	CcSEcCtD
Tacrolimus—Vision blurred—Temozolomide—skin cancer	0.000115	0.000477	CcSEcCtD
Tacrolimus—Myalgia—Dactinomycin—skin cancer	0.000115	0.000477	CcSEcCtD
Tacrolimus—Tremor—Temozolomide—skin cancer	0.000115	0.000475	CcSEcCtD
Tacrolimus—Alopecia—Fluorouracil—skin cancer	0.000114	0.000474	CcSEcCtD
Tacrolimus—Diarrhoea—Imiquimod—skin cancer	0.000114	0.000472	CcSEcCtD
Tacrolimus—Discomfort—Dactinomycin—skin cancer	0.000114	0.000471	CcSEcCtD
Tacrolimus—Angina pectoris—Docetaxel—skin cancer	0.000114	0.000471	CcSEcCtD
Tacrolimus—Ill-defined disorder—Temozolomide—skin cancer	0.000113	0.00047	CcSEcCtD
Tacrolimus—Anaemia—Temozolomide—skin cancer	0.000113	0.000468	CcSEcCtD
Tacrolimus—Anorexia—Bleomycin—skin cancer	0.000113	0.000467	CcSEcCtD
Tacrolimus—Erythema—Fluorouracil—skin cancer	0.000113	0.000467	CcSEcCtD
Tacrolimus—Agitation—Temozolomide—skin cancer	0.000112	0.000465	CcSEcCtD
Tacrolimus—Pancytopenia—Docetaxel—skin cancer	0.000111	0.000459	CcSEcCtD
Tacrolimus—Hypotension—Bleomycin—skin cancer	0.000111	0.000458	CcSEcCtD
Tacrolimus—Oedema—Dactinomycin—skin cancer	0.00011	0.000457	CcSEcCtD
Tacrolimus—Malaise—Temozolomide—skin cancer	0.00011	0.000457	CcSEcCtD
Tacrolimus—Dizziness—Imiquimod—skin cancer	0.00011	0.000456	CcSEcCtD
Tacrolimus—Vertigo—Temozolomide—skin cancer	0.00011	0.000455	CcSEcCtD
Tacrolimus—Infection—Dactinomycin—skin cancer	0.00011	0.000454	CcSEcCtD
Tacrolimus—Leukopenia—Temozolomide—skin cancer	0.000109	0.000453	CcSEcCtD
Tacrolimus—Neutropenia—Docetaxel—skin cancer	0.000109	0.000452	CcSEcCtD
Tacrolimus—Palpitations—Temozolomide—skin cancer	0.000108	0.000448	CcSEcCtD
Tacrolimus—Thrombocytopenia—Dactinomycin—skin cancer	0.000108	0.000447	CcSEcCtD
Tacrolimus—Musculoskeletal discomfort—Bleomycin—skin cancer	0.000108	0.000446	CcSEcCtD
Tacrolimus—Cough—Temozolomide—skin cancer	0.000107	0.000442	CcSEcCtD
Tacrolimus—Paraesthesia—Bleomycin—skin cancer	0.000106	0.00044	CcSEcCtD
Tacrolimus—Weight increased—Docetaxel—skin cancer	0.000106	0.00044	CcSEcCtD
Tacrolimus—Vision blurred—Fluorouracil—skin cancer	0.000106	0.00044	CcSEcCtD
Tacrolimus—Convulsion—Temozolomide—skin cancer	0.000106	0.000439	CcSEcCtD
Tacrolimus—Vomiting—Imiquimod—skin cancer	0.000106	0.000439	CcSEcCtD
Tacrolimus—Weight decreased—Docetaxel—skin cancer	0.000106	0.000437	CcSEcCtD
Tacrolimus—Hypertension—Temozolomide—skin cancer	0.000106	0.000437	CcSEcCtD
Tacrolimus—Dyspnoea—Bleomycin—skin cancer	0.000106	0.000437	CcSEcCtD
Tacrolimus—Anorexia—Dactinomycin—skin cancer	0.000105	0.000436	CcSEcCtD
Tacrolimus—Rash—Imiquimod—skin cancer	0.000105	0.000435	CcSEcCtD
Tacrolimus—Dermatitis—Imiquimod—skin cancer	0.000105	0.000435	CcSEcCtD
Tacrolimus—Pneumonia—Docetaxel—skin cancer	0.000105	0.000434	CcSEcCtD
Tacrolimus—Headache—Imiquimod—skin cancer	0.000104	0.000432	CcSEcCtD
Tacrolimus—Anaemia—Fluorouracil—skin cancer	0.000104	0.000431	CcSEcCtD
Tacrolimus—Myalgia—Temozolomide—skin cancer	0.000104	0.000431	CcSEcCtD
Tacrolimus—Arthralgia—Temozolomide—skin cancer	0.000104	0.000431	CcSEcCtD
Tacrolimus—Infestation NOS—Docetaxel—skin cancer	0.000104	0.000431	CcSEcCtD
Tacrolimus—Infestation—Docetaxel—skin cancer	0.000104	0.000431	CcSEcCtD
Tacrolimus—Anxiety—Temozolomide—skin cancer	0.000104	0.00043	CcSEcCtD
Tacrolimus—Unspecified disorder of skin and subcutaneous tissue—Temozolomide—skin cancer	0.000103	0.000428	CcSEcCtD
Tacrolimus—Stevens-Johnson syndrome—Docetaxel—skin cancer	0.000103	0.000427	CcSEcCtD
Tacrolimus—Discomfort—Temozolomide—skin cancer	0.000103	0.000426	CcSEcCtD
Tacrolimus—Decreased appetite—Bleomycin—skin cancer	0.000103	0.000426	CcSEcCtD
Tacrolimus—Acute coronary syndrome—Docetaxel—skin cancer	0.000103	0.000425	CcSEcCtD
Tacrolimus—Renal failure—Docetaxel—skin cancer	0.000102	0.000424	CcSEcCtD
Tacrolimus—Myocardial infarction—Docetaxel—skin cancer	0.000102	0.000423	CcSEcCtD
Tacrolimus—Neuropathy peripheral—Docetaxel—skin cancer	0.000102	0.000423	CcSEcCtD
Tacrolimus—Dry mouth—Temozolomide—skin cancer	0.000102	0.000422	CcSEcCtD
Tacrolimus—Stomatitis—Docetaxel—skin cancer	0.000101	0.00042	CcSEcCtD
Tacrolimus—Jaundice—Docetaxel—skin cancer	0.000101	0.00042	CcSEcCtD
Tacrolimus—Pain—Bleomycin—skin cancer	0.000101	0.000419	CcSEcCtD
Tacrolimus—Conjunctivitis—Docetaxel—skin cancer	0.000101	0.000419	CcSEcCtD
Tacrolimus—Leukopenia—Fluorouracil—skin cancer	0.000101	0.000418	CcSEcCtD
Tacrolimus—Confusional state—Temozolomide—skin cancer	0.000101	0.000417	CcSEcCtD
Tacrolimus—Musculoskeletal discomfort—Dactinomycin—skin cancer	0.000101	0.000416	CcSEcCtD
Tacrolimus—Anaphylactic shock—Temozolomide—skin cancer	9.98e-05	0.000413	CcSEcCtD
Tacrolimus—Oedema—Temozolomide—skin cancer	9.98e-05	0.000413	CcSEcCtD
Tacrolimus—Infection—Temozolomide—skin cancer	9.92e-05	0.000411	CcSEcCtD
Tacrolimus—Nausea—Imiquimod—skin cancer	9.89e-05	0.00041	CcSEcCtD
Tacrolimus—Hepatobiliary disease—Docetaxel—skin cancer	9.84e-05	0.000408	CcSEcCtD
Tacrolimus—Epistaxis—Docetaxel—skin cancer	9.82e-05	0.000407	CcSEcCtD
Tacrolimus—Nervous system disorder—Temozolomide—skin cancer	9.79e-05	0.000405	CcSEcCtD
Tacrolimus—Thrombocytopenia—Temozolomide—skin cancer	9.77e-05	0.000405	CcSEcCtD
Tacrolimus—Convulsion—Fluorouracil—skin cancer	9.76e-05	0.000404	CcSEcCtD
Tacrolimus—Feeling abnormal—Bleomycin—skin cancer	9.75e-05	0.000404	CcSEcCtD
Tacrolimus—Agranulocytosis—Docetaxel—skin cancer	9.71e-05	0.000402	CcSEcCtD
Tacrolimus—Skin disorder—Temozolomide—skin cancer	9.7e-05	0.000402	CcSEcCtD
Tacrolimus—Hyperhidrosis—Temozolomide—skin cancer	9.65e-05	0.0004	CcSEcCtD
Tacrolimus—Myalgia—Fluorouracil—skin cancer	9.59e-05	0.000397	CcSEcCtD
Tacrolimus—Chest pain—Fluorouracil—skin cancer	9.59e-05	0.000397	CcSEcCtD
Tacrolimus—Decreased appetite—Dactinomycin—skin cancer	9.59e-05	0.000397	CcSEcCtD
Tacrolimus—Fatigue—Dactinomycin—skin cancer	9.52e-05	0.000394	CcSEcCtD
Tacrolimus—Anorexia—Temozolomide—skin cancer	9.52e-05	0.000394	CcSEcCtD
Tacrolimus—Discomfort—Fluorouracil—skin cancer	9.48e-05	0.000393	CcSEcCtD
Tacrolimus—Pain—Dactinomycin—skin cancer	9.44e-05	0.000391	CcSEcCtD
Tacrolimus—Urticaria—Bleomycin—skin cancer	9.4e-05	0.000389	CcSEcCtD
Tacrolimus—Haemoglobin—Docetaxel—skin cancer	9.39e-05	0.000389	CcSEcCtD
Tacrolimus—Rhinitis—Docetaxel—skin cancer	9.37e-05	0.000388	CcSEcCtD
Tacrolimus—Body temperature increased—Bleomycin—skin cancer	9.36e-05	0.000387	CcSEcCtD
Tacrolimus—Haemorrhage—Docetaxel—skin cancer	9.34e-05	0.000387	CcSEcCtD
Tacrolimus—Hepatitis—Docetaxel—skin cancer	9.34e-05	0.000387	CcSEcCtD
Tacrolimus—Hypoaesthesia—Docetaxel—skin cancer	9.3e-05	0.000385	CcSEcCtD
Tacrolimus—Confusional state—Fluorouracil—skin cancer	9.27e-05	0.000384	CcSEcCtD
Tacrolimus—Pharyngitis—Docetaxel—skin cancer	9.27e-05	0.000384	CcSEcCtD
Tacrolimus—Urinary tract disorder—Docetaxel—skin cancer	9.23e-05	0.000382	CcSEcCtD
Tacrolimus—Oedema peripheral—Docetaxel—skin cancer	9.21e-05	0.000381	CcSEcCtD
Tacrolimus—Anaphylactic shock—Fluorouracil—skin cancer	9.2e-05	0.000381	CcSEcCtD
Tacrolimus—Oedema—Fluorouracil—skin cancer	9.2e-05	0.000381	CcSEcCtD
Tacrolimus—Connective tissue disorder—Docetaxel—skin cancer	9.18e-05	0.00038	CcSEcCtD
Tacrolimus—Urethral disorder—Docetaxel—skin cancer	9.16e-05	0.000379	CcSEcCtD
Tacrolimus—Infection—Fluorouracil—skin cancer	9.14e-05	0.000378	CcSEcCtD
Tacrolimus—Feeling abnormal—Dactinomycin—skin cancer	9.1e-05	0.000377	CcSEcCtD
Tacrolimus—Musculoskeletal discomfort—Temozolomide—skin cancer	9.1e-05	0.000377	CcSEcCtD
Tacrolimus—Insomnia—Temozolomide—skin cancer	9.03e-05	0.000374	CcSEcCtD
Tacrolimus—Gastrointestinal pain—Dactinomycin—skin cancer	9.03e-05	0.000374	CcSEcCtD
Tacrolimus—Nervous system disorder—Fluorouracil—skin cancer	9.02e-05	0.000374	CcSEcCtD
Tacrolimus—Thrombocytopenia—Fluorouracil—skin cancer	9.01e-05	0.000373	CcSEcCtD
Tacrolimus—Visual impairment—Docetaxel—skin cancer	9e-05	0.000373	CcSEcCtD
Tacrolimus—Tachycardia—Fluorouracil—skin cancer	8.98e-05	0.000372	CcSEcCtD
Tacrolimus—Paraesthesia—Temozolomide—skin cancer	8.96e-05	0.000371	CcSEcCtD
Tacrolimus—Dyspnoea—Temozolomide—skin cancer	8.9e-05	0.000369	CcSEcCtD
Tacrolimus—Somnolence—Temozolomide—skin cancer	8.87e-05	0.000368	CcSEcCtD
Tacrolimus—Erythema multiforme—Docetaxel—skin cancer	8.84e-05	0.000366	CcSEcCtD
Tacrolimus—Dyspepsia—Temozolomide—skin cancer	8.79e-05	0.000364	CcSEcCtD
Tacrolimus—Anorexia—Fluorouracil—skin cancer	8.77e-05	0.000363	CcSEcCtD
Tacrolimus—Eye disorder—Docetaxel—skin cancer	8.73e-05	0.000362	CcSEcCtD
Tacrolimus—Abdominal pain—Dactinomycin—skin cancer	8.73e-05	0.000361	CcSEcCtD
Tacrolimus—Body temperature increased—Dactinomycin—skin cancer	8.73e-05	0.000361	CcSEcCtD
Tacrolimus—Hypersensitivity—Bleomycin—skin cancer	8.72e-05	0.000361	CcSEcCtD
Tacrolimus—Decreased appetite—Temozolomide—skin cancer	8.68e-05	0.000359	CcSEcCtD
Tacrolimus—Flushing—Docetaxel—skin cancer	8.67e-05	0.000359	CcSEcCtD
Tacrolimus—Cardiac disorder—Docetaxel—skin cancer	8.67e-05	0.000359	CcSEcCtD
Tacrolimus—Gastrointestinal disorder—Temozolomide—skin cancer	8.62e-05	0.000357	CcSEcCtD
Tacrolimus—Fatigue—Temozolomide—skin cancer	8.61e-05	0.000356	CcSEcCtD
Tacrolimus—Hypotension—Fluorouracil—skin cancer	8.59e-05	0.000356	CcSEcCtD
Tacrolimus—Pain—Temozolomide—skin cancer	8.54e-05	0.000354	CcSEcCtD
Tacrolimus—Constipation—Temozolomide—skin cancer	8.54e-05	0.000354	CcSEcCtD
Tacrolimus—Asthenia—Bleomycin—skin cancer	8.49e-05	0.000352	CcSEcCtD
Tacrolimus—Angiopathy—Docetaxel—skin cancer	8.48e-05	0.000351	CcSEcCtD
Tacrolimus—Immune system disorder—Docetaxel—skin cancer	8.44e-05	0.00035	CcSEcCtD
Tacrolimus—Mediastinal disorder—Docetaxel—skin cancer	8.42e-05	0.000349	CcSEcCtD
Tacrolimus—Chills—Docetaxel—skin cancer	8.38e-05	0.000347	CcSEcCtD
Tacrolimus—Musculoskeletal discomfort—Fluorouracil—skin cancer	8.38e-05	0.000347	CcSEcCtD
Tacrolimus—Pruritus—Bleomycin—skin cancer	8.37e-05	0.000347	CcSEcCtD
Tacrolimus—Arrhythmia—Docetaxel—skin cancer	8.35e-05	0.000346	CcSEcCtD
Tacrolimus—Insomnia—Fluorouracil—skin cancer	8.32e-05	0.000344	CcSEcCtD
Tacrolimus—Paraesthesia—Fluorouracil—skin cancer	8.26e-05	0.000342	CcSEcCtD
Tacrolimus—Alopecia—Docetaxel—skin cancer	8.26e-05	0.000342	CcSEcCtD
Tacrolimus—Feeling abnormal—Temozolomide—skin cancer	8.23e-05	0.000341	CcSEcCtD
Tacrolimus—Dyspnoea—Fluorouracil—skin cancer	8.2e-05	0.00034	CcSEcCtD
Tacrolimus—Mental disorder—Docetaxel—skin cancer	8.19e-05	0.000339	CcSEcCtD
Tacrolimus—Somnolence—Fluorouracil—skin cancer	8.18e-05	0.000339	CcSEcCtD
Tacrolimus—Gastrointestinal pain—Temozolomide—skin cancer	8.16e-05	0.000338	CcSEcCtD
Tacrolimus—Erythema—Docetaxel—skin cancer	8.13e-05	0.000337	CcSEcCtD
Tacrolimus—Malnutrition—Docetaxel—skin cancer	8.13e-05	0.000337	CcSEcCtD
Tacrolimus—Hypersensitivity—Dactinomycin—skin cancer	8.13e-05	0.000337	CcSEcCtD
Tacrolimus—Dyspepsia—Fluorouracil—skin cancer	8.1e-05	0.000335	CcSEcCtD
Tacrolimus—Decreased appetite—Fluorouracil—skin cancer	8e-05	0.000331	CcSEcCtD
Tacrolimus—Dysgeusia—Docetaxel—skin cancer	7.97e-05	0.00033	CcSEcCtD
Tacrolimus—Gastrointestinal disorder—Fluorouracil—skin cancer	7.94e-05	0.000329	CcSEcCtD
Tacrolimus—Urticaria—Temozolomide—skin cancer	7.93e-05	0.000328	CcSEcCtD
Tacrolimus—Asthenia—Dactinomycin—skin cancer	7.92e-05	0.000328	CcSEcCtD
Tacrolimus—Body temperature increased—Temozolomide—skin cancer	7.89e-05	0.000327	CcSEcCtD
Tacrolimus—Abdominal pain—Temozolomide—skin cancer	7.89e-05	0.000327	CcSEcCtD
Tacrolimus—Back pain—Docetaxel—skin cancer	7.87e-05	0.000326	CcSEcCtD
Tacrolimus—Pain—Fluorouracil—skin cancer	7.87e-05	0.000326	CcSEcCtD
Tacrolimus—Muscle spasms—Docetaxel—skin cancer	7.82e-05	0.000324	CcSEcCtD
Tacrolimus—Feeling abnormal—Fluorouracil—skin cancer	7.58e-05	0.000314	CcSEcCtD
Tacrolimus—Diarrhoea—Dactinomycin—skin cancer	7.55e-05	0.000313	CcSEcCtD
Tacrolimus—Vomiting—Bleomycin—skin cancer	7.52e-05	0.000312	CcSEcCtD
Tacrolimus—Anaemia—Docetaxel—skin cancer	7.52e-05	0.000311	CcSEcCtD
Tacrolimus—Rash—Bleomycin—skin cancer	7.46e-05	0.000309	CcSEcCtD
Tacrolimus—Dermatitis—Bleomycin—skin cancer	7.45e-05	0.000309	CcSEcCtD
Tacrolimus—Hypersensitivity—Temozolomide—skin cancer	7.35e-05	0.000305	CcSEcCtD
Tacrolimus—Urticaria—Fluorouracil—skin cancer	7.31e-05	0.000303	CcSEcCtD
Tacrolimus—Syncope—Docetaxel—skin cancer	7.29e-05	0.000302	CcSEcCtD
Tacrolimus—Leukopenia—Docetaxel—skin cancer	7.28e-05	0.000302	CcSEcCtD
Tacrolimus—Body temperature increased—Fluorouracil—skin cancer	7.27e-05	0.000301	CcSEcCtD
Tacrolimus—Palpitations—Docetaxel—skin cancer	7.19e-05	0.000298	CcSEcCtD
Tacrolimus—Asthenia—Temozolomide—skin cancer	7.16e-05	0.000297	CcSEcCtD
Tacrolimus—Loss of consciousness—Docetaxel—skin cancer	7.15e-05	0.000296	CcSEcCtD
Tacrolimus—Cough—Docetaxel—skin cancer	7.1e-05	0.000294	CcSEcCtD
Tacrolimus—Pruritus—Temozolomide—skin cancer	7.06e-05	0.000292	CcSEcCtD
Tacrolimus—Convulsion—Docetaxel—skin cancer	7.05e-05	0.000292	CcSEcCtD
Tacrolimus—Nausea—Bleomycin—skin cancer	7.03e-05	0.000291	CcSEcCtD
Tacrolimus—Hypertension—Docetaxel—skin cancer	7.02e-05	0.000291	CcSEcCtD
Tacrolimus—Vomiting—Dactinomycin—skin cancer	7.02e-05	0.000291	CcSEcCtD
Tacrolimus—Rash—Dactinomycin—skin cancer	6.96e-05	0.000288	CcSEcCtD
Tacrolimus—Arthralgia—Docetaxel—skin cancer	6.93e-05	0.000287	CcSEcCtD
Tacrolimus—Myalgia—Docetaxel—skin cancer	6.93e-05	0.000287	CcSEcCtD
Tacrolimus—Chest pain—Docetaxel—skin cancer	6.93e-05	0.000287	CcSEcCtD
Tacrolimus—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—skin cancer	6.88e-05	0.000285	CcSEcCtD
Tacrolimus—Diarrhoea—Temozolomide—skin cancer	6.83e-05	0.000283	CcSEcCtD
Tacrolimus—Hypersensitivity—Fluorouracil—skin cancer	6.78e-05	0.000281	CcSEcCtD
Tacrolimus—Dry mouth—Docetaxel—skin cancer	6.77e-05	0.00028	CcSEcCtD
Tacrolimus—Confusional state—Docetaxel—skin cancer	6.69e-05	0.000277	CcSEcCtD
Tacrolimus—Anaphylactic shock—Docetaxel—skin cancer	6.64e-05	0.000275	CcSEcCtD
Tacrolimus—Oedema—Docetaxel—skin cancer	6.64e-05	0.000275	CcSEcCtD
Tacrolimus—Dizziness—Temozolomide—skin cancer	6.6e-05	0.000273	CcSEcCtD
Tacrolimus—Infection—Docetaxel—skin cancer	6.6e-05	0.000273	CcSEcCtD
Tacrolimus—Nausea—Dactinomycin—skin cancer	6.56e-05	0.000271	CcSEcCtD
Tacrolimus—Shock—Docetaxel—skin cancer	6.53e-05	0.00027	CcSEcCtD
Tacrolimus—Nervous system disorder—Docetaxel—skin cancer	6.51e-05	0.00027	CcSEcCtD
Tacrolimus—Pruritus—Fluorouracil—skin cancer	6.51e-05	0.000269	CcSEcCtD
Tacrolimus—Thrombocytopenia—Docetaxel—skin cancer	6.5e-05	0.000269	CcSEcCtD
Tacrolimus—Tachycardia—Docetaxel—skin cancer	6.48e-05	0.000268	CcSEcCtD
Tacrolimus—Skin disorder—Docetaxel—skin cancer	6.45e-05	0.000267	CcSEcCtD
Tacrolimus—Vomiting—Temozolomide—skin cancer	6.35e-05	0.000263	CcSEcCtD
Tacrolimus—Anorexia—Docetaxel—skin cancer	6.33e-05	0.000262	CcSEcCtD
Tacrolimus—Rash—Temozolomide—skin cancer	6.29e-05	0.000261	CcSEcCtD
Tacrolimus—Diarrhoea—Fluorouracil—skin cancer	6.29e-05	0.000261	CcSEcCtD
Tacrolimus—Dermatitis—Temozolomide—skin cancer	6.29e-05	0.00026	CcSEcCtD
Tacrolimus—Headache—Temozolomide—skin cancer	6.25e-05	0.000259	CcSEcCtD
Tacrolimus—Hypotension—Docetaxel—skin cancer	6.2e-05	0.000257	CcSEcCtD
Tacrolimus—Dizziness—Fluorouracil—skin cancer	6.08e-05	0.000252	CcSEcCtD
Tacrolimus—Musculoskeletal discomfort—Docetaxel—skin cancer	6.05e-05	0.00025	CcSEcCtD
Tacrolimus—Insomnia—Docetaxel—skin cancer	6e-05	0.000249	CcSEcCtD
Tacrolimus—Paraesthesia—Docetaxel—skin cancer	5.96e-05	0.000247	CcSEcCtD
Tacrolimus—MTOR—Signaling events mediated by Hepatocyte Growth Factor Receptor (c-Met)—HRAS—skin cancer	5.94e-05	0.00182	CbGpPWpGaD
Tacrolimus—Nausea—Temozolomide—skin cancer	5.93e-05	0.000246	CcSEcCtD
Tacrolimus—Dyspnoea—Docetaxel—skin cancer	5.92e-05	0.000245	CcSEcCtD
Tacrolimus—Somnolence—Docetaxel—skin cancer	5.9e-05	0.000244	CcSEcCtD
Tacrolimus—FKBP1A—Disease—ENO2—skin cancer	5.9e-05	0.00181	CbGpPWpGaD
Tacrolimus—FKBP1A—Disease—SHH—skin cancer	5.9e-05	0.00181	CbGpPWpGaD
Tacrolimus—Vomiting—Fluorouracil—skin cancer	5.85e-05	0.000242	CcSEcCtD
Tacrolimus—Dyspepsia—Docetaxel—skin cancer	5.84e-05	0.000242	CcSEcCtD
Tacrolimus—Rash—Fluorouracil—skin cancer	5.8e-05	0.00024	CcSEcCtD
Tacrolimus—FKBP1A—Signaling Pathways—MC1R—skin cancer	5.8e-05	0.00178	CbGpPWpGaD
Tacrolimus—Dermatitis—Fluorouracil—skin cancer	5.79e-05	0.00024	CcSEcCtD
Tacrolimus—Decreased appetite—Docetaxel—skin cancer	5.77e-05	0.000239	CcSEcCtD
Tacrolimus—Headache—Fluorouracil—skin cancer	5.76e-05	0.000239	CcSEcCtD
Tacrolimus—Gastrointestinal disorder—Docetaxel—skin cancer	5.73e-05	0.000237	CcSEcCtD
Tacrolimus—Fatigue—Docetaxel—skin cancer	5.72e-05	0.000237	CcSEcCtD
Tacrolimus—FKBP1A—Signaling Pathways—GLI1—skin cancer	5.71e-05	0.00175	CbGpPWpGaD
Tacrolimus—MTOR—Immune System—TLR7—skin cancer	5.68e-05	0.00174	CbGpPWpGaD
Tacrolimus—Constipation—Docetaxel—skin cancer	5.68e-05	0.000235	CcSEcCtD
Tacrolimus—Pain—Docetaxel—skin cancer	5.68e-05	0.000235	CcSEcCtD
Tacrolimus—MTOR—IRS-mediated signalling—HRAS—skin cancer	5.66e-05	0.00174	CbGpPWpGaD
Tacrolimus—MTOR—ErbB1 downstream signaling—KRAS—skin cancer	5.62e-05	0.00173	CbGpPWpGaD
Tacrolimus—MTOR—Cellular responses to stress—CDK4—skin cancer	5.62e-05	0.00172	CbGpPWpGaD
Tacrolimus—ALB—Metabolism of lipids and lipoproteins—PLIN2—skin cancer	5.59e-05	0.00172	CbGpPWpGaD
Tacrolimus—MTOR—VEGFA-VEGFR2 Pathway—KRAS—skin cancer	5.54e-05	0.0017	CbGpPWpGaD
Tacrolimus—FKBP1A—Integrated Pancreatic Cancer Pathway—TP53—skin cancer	5.5e-05	0.00169	CbGpPWpGaD
Tacrolimus—MTOR—IRS-related events—HRAS—skin cancer	5.5e-05	0.00169	CbGpPWpGaD
Tacrolimus—Feeling abnormal—Docetaxel—skin cancer	5.47e-05	0.000227	CcSEcCtD
Tacrolimus—Nausea—Fluorouracil—skin cancer	5.46e-05	0.000226	CcSEcCtD
Tacrolimus—MTOR—IRS-related events triggered by IGF1R—HRAS—skin cancer	5.45e-05	0.00167	CbGpPWpGaD
Tacrolimus—Gastrointestinal pain—Docetaxel—skin cancer	5.43e-05	0.000225	CcSEcCtD
Tacrolimus—MTOR—IRS-mediated signalling—IL6—skin cancer	5.42e-05	0.00166	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—SUFU—skin cancer	5.41e-05	0.00166	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling Pathways—SHH—skin cancer	5.33e-05	0.00163	CbGpPWpGaD
Tacrolimus—MTOR—Insulin receptor signalling cascade—HRAS—skin cancer	5.31e-05	0.00163	CbGpPWpGaD
Tacrolimus—MTOR—IGF1R signaling cascade—HRAS—skin cancer	5.31e-05	0.00163	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling Pathways—RASA1—skin cancer	5.29e-05	0.00162	CbGpPWpGaD
Tacrolimus—MTOR—IRS-related events—IL6—skin cancer	5.27e-05	0.00162	CbGpPWpGaD
Tacrolimus—Body temperature increased—Docetaxel—skin cancer	5.25e-05	0.000217	CcSEcCtD
Tacrolimus—Abdominal pain—Docetaxel—skin cancer	5.25e-05	0.000217	CcSEcCtD
Tacrolimus—MTOR—Signaling by VEGF—KRAS—skin cancer	5.23e-05	0.0016	CbGpPWpGaD
Tacrolimus—MTOR—IRS-related events triggered by IGF1R—IL6—skin cancer	5.22e-05	0.0016	CbGpPWpGaD
Tacrolimus—MTOR—Signaling by Insulin receptor—KRAS—skin cancer	5.19e-05	0.00159	CbGpPWpGaD
Tacrolimus—MTOR—Signaling by SCF-KIT—NRAS—skin cancer	5.16e-05	0.00158	CbGpPWpGaD
Tacrolimus—MTOR—Insulin receptor signalling cascade—IL6—skin cancer	5.08e-05	0.00156	CbGpPWpGaD
Tacrolimus—MTOR—IGF1R signaling cascade—IL6—skin cancer	5.08e-05	0.00156	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling Pathways—PTCH1—skin cancer	5.05e-05	0.00155	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling Pathways—SMO—skin cancer	5.05e-05	0.00155	CbGpPWpGaD
Tacrolimus—ALB—Transmembrane transport of small molecules—SLC12A2—skin cancer	5.04e-05	0.00155	CbGpPWpGaD
Tacrolimus—MTOR—Innate Immune System—FOXO4—skin cancer	5.03e-05	0.00154	CbGpPWpGaD
Tacrolimus—MTOR—Senescence and Autophagy in Cancer—TP53—skin cancer	5e-05	0.00153	CbGpPWpGaD
Tacrolimus—MTOR—Downstream signaling of activated FGFR—NRAS—skin cancer	4.94e-05	0.00152	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling Pathways—PTGER4—skin cancer	4.91e-05	0.00151	CbGpPWpGaD
Tacrolimus—Hypersensitivity—Docetaxel—skin cancer	4.89e-05	0.000203	CcSEcCtD
Tacrolimus—MTOR—Disease—CSPG4—skin cancer	4.88e-05	0.0015	CbGpPWpGaD
Tacrolimus—MTOR—Signaling by ERBB4—NRAS—skin cancer	4.86e-05	0.00149	CbGpPWpGaD
Tacrolimus—MTOR—Adaptive Immune System—FOXO4—skin cancer	4.83e-05	0.00148	CbGpPWpGaD
Tacrolimus—FKBP1A—Disease—FOXO4—skin cancer	4.81e-05	0.00148	CbGpPWpGaD
Tacrolimus—MTOR—ErbB1 downstream signaling—HRAS—skin cancer	4.78e-05	0.00147	CbGpPWpGaD
Tacrolimus—MTOR—Senescence and Autophagy in Cancer—HRAS—skin cancer	4.78e-05	0.00147	CbGpPWpGaD
Tacrolimus—Asthenia—Docetaxel—skin cancer	4.76e-05	0.000197	CcSEcCtD
Tacrolimus—ALB—Selenium Micronutrient Network—PTGS2—skin cancer	4.75e-05	0.00146	CbGpPWpGaD
Tacrolimus—MTOR—VEGFA-VEGFR2 Pathway—HRAS—skin cancer	4.71e-05	0.00144	CbGpPWpGaD
Tacrolimus—Pruritus—Docetaxel—skin cancer	4.7e-05	0.000194	CcSEcCtD
Tacrolimus—MTOR—Signaling by NGF—BRAF—skin cancer	4.66e-05	0.00143	CbGpPWpGaD
Tacrolimus—MTOR—Downstream signal transduction—NRAS—skin cancer	4.64e-05	0.00142	CbGpPWpGaD
Tacrolimus—MTOR—Signaling by FGFR—NRAS—skin cancer	4.62e-05	0.00142	CbGpPWpGaD
Tacrolimus—MTOR—Signaling by ERBB2—NRAS—skin cancer	4.59e-05	0.00141	CbGpPWpGaD
Tacrolimus—MTOR—Senescence and Autophagy in Cancer—IL6—skin cancer	4.57e-05	0.0014	CbGpPWpGaD
Tacrolimus—MTOR—DAP12 signaling—NRAS—skin cancer	4.57e-05	0.0014	CbGpPWpGaD
Tacrolimus—Diarrhoea—Docetaxel—skin cancer	4.54e-05	0.000188	CcSEcCtD
Tacrolimus—MTOR—Signaling Pathways—PTCH2—skin cancer	4.51e-05	0.00138	CbGpPWpGaD
Tacrolimus—MTOR—Downstream signaling events of B Cell Receptor (BCR)—NRAS—skin cancer	4.51e-05	0.00138	CbGpPWpGaD
Tacrolimus—MTOR—VEGFA-VEGFR2 Pathway—IL6—skin cancer	4.5e-05	0.00138	CbGpPWpGaD
Tacrolimus—MTOR—Signaling by VEGF—HRAS—skin cancer	4.44e-05	0.00136	CbGpPWpGaD
Tacrolimus—MTOR—Signaling by SCF-KIT—KRAS—skin cancer	4.44e-05	0.00136	CbGpPWpGaD
Tacrolimus—PPP3CA—Disease—ERCC2—skin cancer	4.42e-05	0.00136	CbGpPWpGaD
Tacrolimus—ABCB1—Transmembrane transport of small molecules—SLC12A2—skin cancer	4.42e-05	0.00136	CbGpPWpGaD
Tacrolimus—MTOR—Signaling by Insulin receptor—HRAS—skin cancer	4.41e-05	0.00135	CbGpPWpGaD
Tacrolimus—Dizziness—Docetaxel—skin cancer	4.39e-05	0.000182	CcSEcCtD
Tacrolimus—PPP3CA—Signaling Pathways—FOXO4—skin cancer	4.34e-05	0.00133	CbGpPWpGaD
Tacrolimus—MTOR—DAP12 interactions—NRAS—skin cancer	4.3e-05	0.00132	CbGpPWpGaD
Tacrolimus—MTOR—Signaling by FGFR in disease—NRAS—skin cancer	4.3e-05	0.00132	CbGpPWpGaD
Tacrolimus—MTOR—Fc epsilon receptor (FCERI) signaling—NRAS—skin cancer	4.3e-05	0.00132	CbGpPWpGaD
Tacrolimus—MTOR—Cellular responses to stress—CDKN2A—skin cancer	4.29e-05	0.00132	CbGpPWpGaD
Tacrolimus—MTOR—Signaling by EGFR—NRAS—skin cancer	4.26e-05	0.00131	CbGpPWpGaD
Tacrolimus—MTOR—Signaling by VEGF—IL6—skin cancer	4.25e-05	0.00131	CbGpPWpGaD
Tacrolimus—MTOR—Downstream signaling of activated FGFR—KRAS—skin cancer	4.25e-05	0.0013	CbGpPWpGaD
Tacrolimus—MTOR—Signaling by EGFR in Cancer—NRAS—skin cancer	4.23e-05	0.0013	CbGpPWpGaD
Tacrolimus—MTOR—Signaling by Insulin receptor—IL6—skin cancer	4.22e-05	0.0013	CbGpPWpGaD
Tacrolimus—Vomiting—Docetaxel—skin cancer	4.22e-05	0.000175	CcSEcCtD
Tacrolimus—MTOR—Signaling by PDGF—NRAS—skin cancer	4.21e-05	0.00129	CbGpPWpGaD
Tacrolimus—MTOR—Integrated Breast Cancer Pathway—KRAS—skin cancer	4.2e-05	0.00129	CbGpPWpGaD
Tacrolimus—Rash—Docetaxel—skin cancer	4.19e-05	0.000173	CcSEcCtD
Tacrolimus—Dermatitis—Docetaxel—skin cancer	4.18e-05	0.000173	CcSEcCtD
Tacrolimus—MTOR—Signaling by ERBB4—KRAS—skin cancer	4.18e-05	0.00128	CbGpPWpGaD
Tacrolimus—Headache—Docetaxel—skin cancer	4.16e-05	0.000172	CcSEcCtD
Tacrolimus—PPP3CA—Disease—TERT—skin cancer	4.14e-05	0.00127	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—SHH—skin cancer	4.13e-05	0.00127	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—RASA1—skin cancer	4.1e-05	0.00126	CbGpPWpGaD
Tacrolimus—ALB—Vitamin B12 Metabolism—IL6—skin cancer	4e-05	0.00123	CbGpPWpGaD
Tacrolimus—CYP3A7—Metabolism—PLIN2—skin cancer	4e-05	0.00123	CbGpPWpGaD
Tacrolimus—MTOR—Downstream signal transduction—KRAS—skin cancer	3.99e-05	0.00123	CbGpPWpGaD
Tacrolimus—MTOR—B Cell Activation—NRAS—skin cancer	3.98e-05	0.00122	CbGpPWpGaD
Tacrolimus—MTOR—EGF/EGFR Signaling Pathway—KRAS—skin cancer	3.97e-05	0.00122	CbGpPWpGaD
Tacrolimus—MTOR—Signaling by FGFR—KRAS—skin cancer	3.97e-05	0.00122	CbGpPWpGaD
Tacrolimus—MTOR—Signaling by ERBB2—KRAS—skin cancer	3.95e-05	0.00121	CbGpPWpGaD
Tacrolimus—Nausea—Docetaxel—skin cancer	3.94e-05	0.000163	CcSEcCtD
Tacrolimus—MTOR—DAP12 signaling—KRAS—skin cancer	3.93e-05	0.00121	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—SMO—skin cancer	3.91e-05	0.0012	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—PTCH1—skin cancer	3.91e-05	0.0012	CbGpPWpGaD
Tacrolimus—MTOR—Downstream signaling events of B Cell Receptor (BCR)—KRAS—skin cancer	3.88e-05	0.00119	CbGpPWpGaD
Tacrolimus—PPP3CA—Innate Immune System—NRAS—skin cancer	3.83e-05	0.00118	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—PTGER4—skin cancer	3.81e-05	0.00117	CbGpPWpGaD
Tacrolimus—MTOR—NGF signalling via TRKA from the plasma membrane—NRAS—skin cancer	3.81e-05	0.00117	CbGpPWpGaD
Tacrolimus—MTOR—Signaling by SCF-KIT—HRAS—skin cancer	3.77e-05	0.00116	CbGpPWpGaD
Tacrolimus—MTOR—Integrated Breast Cancer Pathway—TP53—skin cancer	3.74e-05	0.00115	CbGpPWpGaD
Tacrolimus—MTOR—BDNF signaling pathway—HRAS—skin cancer	3.71e-05	0.00114	CbGpPWpGaD
Tacrolimus—MTOR—Fc epsilon receptor (FCERI) signaling—KRAS—skin cancer	3.7e-05	0.00114	CbGpPWpGaD
Tacrolimus—MTOR—Signaling by FGFR in disease—KRAS—skin cancer	3.7e-05	0.00114	CbGpPWpGaD
Tacrolimus—MTOR—DAP12 interactions—KRAS—skin cancer	3.7e-05	0.00114	CbGpPWpGaD
Tacrolimus—MTOR—Signaling by EGFR—KRAS—skin cancer	3.67e-05	0.00113	CbGpPWpGaD
Tacrolimus—MTOR—Signaling by EGFR in Cancer—KRAS—skin cancer	3.64e-05	0.00112	CbGpPWpGaD
Tacrolimus—MTOR—Signaling by PDGF—KRAS—skin cancer	3.62e-05	0.00111	CbGpPWpGaD
Tacrolimus—MTOR—Signaling by SCF-KIT—IL6—skin cancer	3.61e-05	0.00111	CbGpPWpGaD
Tacrolimus—MTOR—Downstream signaling of activated FGFR—HRAS—skin cancer	3.61e-05	0.00111	CbGpPWpGaD
Tacrolimus—ALB—Folate Metabolism—TP53—skin cancer	3.56e-05	0.00109	CbGpPWpGaD
Tacrolimus—MTOR—Signaling by ERBB4—HRAS—skin cancer	3.55e-05	0.00109	CbGpPWpGaD
Tacrolimus—MTOR—Downstream signaling of activated FGFR—IL6—skin cancer	3.46e-05	0.00106	CbGpPWpGaD
Tacrolimus—MTOR—B Cell Activation—KRAS—skin cancer	3.43e-05	0.00105	CbGpPWpGaD
Tacrolimus—FKBP1A—Disease—ERCC2—skin cancer	3.43e-05	0.00105	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—GLI2—skin cancer	3.42e-05	0.00105	CbGpPWpGaD
Tacrolimus—MTOR—Insulin Signaling—HRAS—skin cancer	3.41e-05	0.00105	CbGpPWpGaD
Tacrolimus—MTOR—Signaling by ERBB4—IL6—skin cancer	3.4e-05	0.00104	CbGpPWpGaD
Tacrolimus—MTOR—Downstream signal transduction—HRAS—skin cancer	3.39e-05	0.00104	CbGpPWpGaD
Tacrolimus—MTOR—Signaling by FGFR—HRAS—skin cancer	3.38e-05	0.00104	CbGpPWpGaD
Tacrolimus—MTOR—EGF/EGFR Signaling Pathway—HRAS—skin cancer	3.38e-05	0.00104	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—FOXO4—skin cancer	3.37e-05	0.00103	CbGpPWpGaD
Tacrolimus—MTOR—Signaling by ERBB2—HRAS—skin cancer	3.36e-05	0.00103	CbGpPWpGaD
Tacrolimus—MTOR—DAP12 signaling—HRAS—skin cancer	3.34e-05	0.00103	CbGpPWpGaD
Tacrolimus—MTOR—Disease—SHH—skin cancer	3.32e-05	0.00102	CbGpPWpGaD
Tacrolimus—MTOR—Disease—ENO2—skin cancer	3.32e-05	0.00102	CbGpPWpGaD
Tacrolimus—PPP3CA—Innate Immune System—KRAS—skin cancer	3.3e-05	0.00101	CbGpPWpGaD
Tacrolimus—MTOR—Downstream signaling events of B Cell Receptor (BCR)—HRAS—skin cancer	3.3e-05	0.00101	CbGpPWpGaD
Tacrolimus—PPP3CA—Disease—BRAF—skin cancer	3.28e-05	0.00101	CbGpPWpGaD
Tacrolimus—MTOR—NGF signalling via TRKA from the plasma membrane—KRAS—skin cancer	3.28e-05	0.00101	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—MC1R—skin cancer	3.26e-05	0.001	CbGpPWpGaD
Tacrolimus—ALB—Folate Metabolism—IL6—skin cancer	3.26e-05	0.001	CbGpPWpGaD
Tacrolimus—MTOR—Downstream signal transduction—IL6—skin cancer	3.25e-05	0.000997	CbGpPWpGaD
Tacrolimus—MTOR—Signaling by FGFR—IL6—skin cancer	3.23e-05	0.000992	CbGpPWpGaD
Tacrolimus—CYP3A7—Metabolism—CSPG4—skin cancer	3.22e-05	0.00099	CbGpPWpGaD
Tacrolimus—MTOR—Signaling by ERBB2—IL6—skin cancer	3.22e-05	0.000987	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—GLI1—skin cancer	3.21e-05	0.000986	CbGpPWpGaD
Tacrolimus—FKBP1A—Disease—TERT—skin cancer	3.21e-05	0.000985	CbGpPWpGaD
Tacrolimus—MTOR—DAP12 signaling—IL6—skin cancer	3.2e-05	0.000983	CbGpPWpGaD
Tacrolimus—MTOR—Fc epsilon receptor (FCERI) signaling—HRAS—skin cancer	3.15e-05	0.000966	CbGpPWpGaD
Tacrolimus—MTOR—DAP12 interactions—HRAS—skin cancer	3.15e-05	0.000966	CbGpPWpGaD
Tacrolimus—MTOR—Signaling by FGFR in disease—HRAS—skin cancer	3.15e-05	0.000966	CbGpPWpGaD
Tacrolimus—ABCB1—Integrated Pancreatic Cancer Pathway—CDK4—skin cancer	3.13e-05	0.000962	CbGpPWpGaD
Tacrolimus—MTOR—Signaling by EGFR—HRAS—skin cancer	3.12e-05	0.000957	CbGpPWpGaD
Tacrolimus—MTOR—Signaling by EGFR in Cancer—HRAS—skin cancer	3.09e-05	0.000949	CbGpPWpGaD
Tacrolimus—MTOR—Signaling by PDGF—HRAS—skin cancer	3.08e-05	0.000945	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—SUFU—skin cancer	3.05e-05	0.000935	CbGpPWpGaD
Tacrolimus—MTOR—Signaling by FGFR in disease—IL6—skin cancer	3.01e-05	0.000924	CbGpPWpGaD
Tacrolimus—MTOR—DAP12 interactions—IL6—skin cancer	3.01e-05	0.000924	CbGpPWpGaD
Tacrolimus—MTOR—Fc epsilon receptor (FCERI) signaling—IL6—skin cancer	3.01e-05	0.000924	CbGpPWpGaD
Tacrolimus—MTOR—Signaling by EGFR—IL6—skin cancer	2.98e-05	0.000916	CbGpPWpGaD
Tacrolimus—MTOR—Signaling by EGFR in Cancer—IL6—skin cancer	2.96e-05	0.000908	CbGpPWpGaD
Tacrolimus—MTOR—Signaling by PDGF—IL6—skin cancer	2.95e-05	0.000904	CbGpPWpGaD
Tacrolimus—MTOR—Signaling by NGF—NRAS—skin cancer	2.93e-05	0.000899	CbGpPWpGaD
Tacrolimus—MTOR—Immune System—FOXO4—skin cancer	2.93e-05	0.000899	CbGpPWpGaD
Tacrolimus—MTOR—B Cell Activation—HRAS—skin cancer	2.91e-05	0.000894	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling Pathways—TERT—skin cancer	2.9e-05	0.00089	CbGpPWpGaD
Tacrolimus—CYP3A5—Metabolism—PLIN2—skin cancer	2.89e-05	0.000888	CbGpPWpGaD
Tacrolimus—PPP3CA—Innate Immune System—HRAS—skin cancer	2.8e-05	0.000861	CbGpPWpGaD
Tacrolimus—MTOR—NGF signalling via TRKA from the plasma membrane—HRAS—skin cancer	2.79e-05	0.000855	CbGpPWpGaD
Tacrolimus—MTOR—Disease—FOXO4—skin cancer	2.7e-05	0.00083	CbGpPWpGaD
Tacrolimus—PPP3CA—Innate Immune System—IL6—skin cancer	2.68e-05	0.000824	CbGpPWpGaD
Tacrolimus—MTOR—NGF signalling via TRKA from the plasma membrane—IL6—skin cancer	2.67e-05	0.000819	CbGpPWpGaD
Tacrolimus—PPP3CA—Disease—PTGS2—skin cancer	2.65e-05	0.000813	CbGpPWpGaD
Tacrolimus—ALB—Selenium Micronutrient Network—IL6—skin cancer	2.59e-05	0.000794	CbGpPWpGaD
Tacrolimus—FKBP1A—Disease—BRAF—skin cancer	2.54e-05	0.00078	CbGpPWpGaD
Tacrolimus—MTOR—Signaling by NGF—KRAS—skin cancer	2.52e-05	0.000774	CbGpPWpGaD
Tacrolimus—ALB—Metabolism—PLIN2—skin cancer	2.49e-05	0.000764	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling by GPCR—NRAS—skin cancer	2.44e-05	0.00075	CbGpPWpGaD
Tacrolimus—MTOR—Cellular responses to stress—TP53—skin cancer	2.39e-05	0.000733	CbGpPWpGaD
Tacrolimus—CYP3A5—Metabolism—CSPG4—skin cancer	2.33e-05	0.000715	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—SHH—skin cancer	2.32e-05	0.000713	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—RASA1—skin cancer	2.31e-05	0.000708	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling Pathways—BRAF—skin cancer	2.3e-05	0.000705	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—TERT—skin cancer	2.25e-05	0.00069	CbGpPWpGaD
Tacrolimus—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—skin cancer	2.24e-05	0.000687	CbGpPWpGaD
Tacrolimus—PPP3CA—Immune System—NRAS—skin cancer	2.23e-05	0.000685	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—SMO—skin cancer	2.2e-05	0.000676	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—PTCH1—skin cancer	2.2e-05	0.000676	CbGpPWpGaD
Tacrolimus—CYP3A7—Metabolism—ENO2—skin cancer	2.19e-05	0.000673	CbGpPWpGaD
Tacrolimus—MTOR—Cellular responses to stress—IL6—skin cancer	2.19e-05	0.000671	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—PLIN2—skin cancer	2.18e-05	0.00067	CbGpPWpGaD
Tacrolimus—MTOR—Signaling by NGF—HRAS—skin cancer	2.14e-05	0.000658	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—PTGER4—skin cancer	2.14e-05	0.000658	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling by GPCR—KRAS—skin cancer	2.1e-05	0.000645	CbGpPWpGaD
Tacrolimus—PPP3CA—Disease—NRAS—skin cancer	2.06e-05	0.000633	CbGpPWpGaD
Tacrolimus—FKBP1A—Disease—PTGS2—skin cancer	2.05e-05	0.00063	CbGpPWpGaD
Tacrolimus—MTOR—Signaling by NGF—IL6—skin cancer	2.05e-05	0.00063	CbGpPWpGaD
Tacrolimus—ALB—Metabolism—CSPG4—skin cancer	2.01e-05	0.000616	CbGpPWpGaD
Tacrolimus—MTOR—Disease—ERCC2—skin cancer	1.93e-05	0.000591	CbGpPWpGaD
Tacrolimus—PPP3CA—Immune System—KRAS—skin cancer	1.92e-05	0.00059	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—FOXO4—skin cancer	1.89e-05	0.000581	CbGpPWpGaD
Tacrolimus—MTOR—Disease—TERT—skin cancer	1.81e-05	0.000554	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling by GPCR—HRAS—skin cancer	1.79e-05	0.000549	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—BRAF—skin cancer	1.78e-05	0.000546	CbGpPWpGaD
Tacrolimus—PPP3CA—Disease—KRAS—skin cancer	1.77e-05	0.000544	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—CSPG4—skin cancer	1.76e-05	0.00054	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling by GPCR—IL6—skin cancer	1.71e-05	0.000525	CbGpPWpGaD
Tacrolimus—MTOR—Innate Immune System—NRAS—skin cancer	1.67e-05	0.000513	CbGpPWpGaD
Tacrolimus—PPP3CA—Immune System—HRAS—skin cancer	1.63e-05	0.000501	CbGpPWpGaD
Tacrolimus—MTOR—Adaptive Immune System—NRAS—skin cancer	1.6e-05	0.000493	CbGpPWpGaD
Tacrolimus—FKBP1A—Disease—NRAS—skin cancer	1.6e-05	0.00049	CbGpPWpGaD
Tacrolimus—CYP3A5—Metabolism—ENO2—skin cancer	1.58e-05	0.000486	CbGpPWpGaD
Tacrolimus—PPP3CA—Immune System—IL6—skin cancer	1.56e-05	0.00048	CbGpPWpGaD
Tacrolimus—PPP3CA—Disease—HRAS—skin cancer	1.51e-05	0.000463	CbGpPWpGaD
Tacrolimus—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—skin cancer	1.5e-05	0.00046	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling Pathways—NRAS—skin cancer	1.44e-05	0.000443	CbGpPWpGaD
Tacrolimus—PPP3CA—Disease—IL6—skin cancer	1.44e-05	0.000443	CbGpPWpGaD
Tacrolimus—MTOR—Innate Immune System—KRAS—skin cancer	1.44e-05	0.000441	CbGpPWpGaD
Tacrolimus—MTOR—Disease—BRAF—skin cancer	1.43e-05	0.000439	CbGpPWpGaD
Tacrolimus—MTOR—Adaptive Immune System—KRAS—skin cancer	1.38e-05	0.000424	CbGpPWpGaD
Tacrolimus—FKBP1A—Disease—KRAS—skin cancer	1.38e-05	0.000422	CbGpPWpGaD
Tacrolimus—ALB—Metabolism—ENO2—skin cancer	1.36e-05	0.000419	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—PLIN2—skin cancer	1.34e-05	0.000413	CbGpPWpGaD
Tacrolimus—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—skin cancer	1.33e-05	0.000409	CbGpPWpGaD
Tacrolimus—CYP3A7—Metabolism—ERCC2—skin cancer	1.27e-05	0.000391	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—TERT—skin cancer	1.26e-05	0.000388	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling Pathways—KRAS—skin cancer	1.24e-05	0.000381	CbGpPWpGaD
Tacrolimus—MTOR—Innate Immune System—HRAS—skin cancer	1.22e-05	0.000375	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—ENO2—skin cancer	1.2e-05	0.000367	CbGpPWpGaD
Tacrolimus—MTOR—Adaptive Immune System—HRAS—skin cancer	1.17e-05	0.00036	CbGpPWpGaD
Tacrolimus—MTOR—Innate Immune System—IL6—skin cancer	1.17e-05	0.000359	CbGpPWpGaD
Tacrolimus—FKBP1A—Disease—HRAS—skin cancer	1.17e-05	0.000359	CbGpPWpGaD
Tacrolimus—MTOR—Disease—PTGS2—skin cancer	1.16e-05	0.000355	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—NRAS—skin cancer	1.12e-05	0.000343	CbGpPWpGaD
Tacrolimus—FKBP1A—Disease—IL6—skin cancer	1.12e-05	0.000343	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling Pathways—TP53—skin cancer	1.1e-05	0.000339	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—CSPG4—skin cancer	1.08e-05	0.000333	CbGpPWpGaD
Tacrolimus—ALB—Metabolism of lipids and lipoproteins—PTGS2—skin cancer	1.07e-05	0.000328	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling Pathways—HRAS—skin cancer	1.06e-05	0.000324	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling Pathways—IL6—skin cancer	1.01e-05	0.00031	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—BRAF—skin cancer	1e-05	0.000307	CbGpPWpGaD
Tacrolimus—MTOR—Immune System—NRAS—skin cancer	9.73e-06	0.000299	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—KRAS—skin cancer	9.63e-06	0.000296	CbGpPWpGaD
Tacrolimus—CYP3A5—Metabolism—ERCC2—skin cancer	9.2e-06	0.000282	CbGpPWpGaD
Tacrolimus—ALB—Hemostasis—NRAS—skin cancer	9.12e-06	0.00028	CbGpPWpGaD
Tacrolimus—MTOR—Disease—NRAS—skin cancer	8.99e-06	0.000276	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—TP53—skin cancer	8.56e-06	0.000263	CbGpPWpGaD
Tacrolimus—MTOR—Immune System—KRAS—skin cancer	8.38e-06	0.000257	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—HRAS—skin cancer	8.19e-06	0.000251	CbGpPWpGaD
Tacrolimus—ALB—Metabolism—ERCC2—skin cancer	7.93e-06	0.000243	CbGpPWpGaD
Tacrolimus—ALB—Hemostasis—KRAS—skin cancer	7.85e-06	0.000241	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—IL6—skin cancer	7.84e-06	0.00024	CbGpPWpGaD
Tacrolimus—MTOR—Disease—KRAS—skin cancer	7.73e-06	0.000237	CbGpPWpGaD
Tacrolimus—CYP3A7—Metabolism—PTGS2—skin cancer	7.63e-06	0.000234	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—ENO2—skin cancer	7.37e-06	0.000226	CbGpPWpGaD
Tacrolimus—MTOR—Immune System—HRAS—skin cancer	7.12e-06	0.000219	CbGpPWpGaD
Tacrolimus—ALB—Hemostasis—TP53—skin cancer	6.98e-06	0.000214	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—ERCC2—skin cancer	6.95e-06	0.000213	CbGpPWpGaD
Tacrolimus—MTOR—Immune System—IL6—skin cancer	6.82e-06	0.000209	CbGpPWpGaD
Tacrolimus—ALB—Hemostasis—HRAS—skin cancer	6.67e-06	0.000205	CbGpPWpGaD
Tacrolimus—MTOR—Disease—HRAS—skin cancer	6.57e-06	0.000202	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—NRAS—skin cancer	6.29e-06	0.000193	CbGpPWpGaD
Tacrolimus—MTOR—Disease—IL6—skin cancer	6.29e-06	0.000193	CbGpPWpGaD
Tacrolimus—CYP3A5—Metabolism—PTGS2—skin cancer	5.52e-06	0.000169	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—KRAS—skin cancer	5.42e-06	0.000166	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—TP53—skin cancer	4.81e-06	0.000148	CbGpPWpGaD
Tacrolimus—ALB—Metabolism—PTGS2—skin cancer	4.75e-06	0.000146	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—HRAS—skin cancer	4.6e-06	0.000141	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—IL6—skin cancer	4.41e-06	0.000135	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—ERCC2—skin cancer	4.28e-06	0.000131	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—PTGS2—skin cancer	4.16e-06	0.000128	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—PTGS2—skin cancer	2.57e-06	7.87e-05	CbGpPWpGaD
